GlobeImmune, Gilead Hep B drug fails in mid-stage study

GlobeImmune

27/05/2015 11:50

May 27 (Reuters) - GlobeImmune Inc  GBIM.O  said its 
experimental hepatitis B drug did not meet the main goal of 
reducing infection in patients after 24 weeks, in a mid-stage 
trial.  
    However, the drug was found to reduce HBsAg, an antigen that 
indicates the strength of hepatitis B infection, after 48 weeks, 
the company said on Wednesday.  ID:nMKW2SH1ra  
    GlobeImmune is developing the drug, GS-4774, with Gilead 
Sciences Inc  GILD.O .  
 
 (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti 
Pandey) 
 ((penumudi.amrutha@thomsonreuters.com; within U.S. +1 646 223 
8780 outside U.S. +91 80 6749 4486; Reuters Messaging: 
penumudi.amrutha.thomsonreuters.com@reuters.net)) 
 
Keywords: GLOBEIMMUNE STUDY/HEPATITIS